{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-027235","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.197951+00:00","generated_at":"2026-05-31T20:54:08.140735+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enveric licenses radiation dermatitis product to Aries; eligible for up to $61M in milestones","bullets":["Akos (Enveric sub) grants Aries exclusive worldwide license for patented radiation dermatitis topical.","Enveric eligible for up to $61M in aggregate milestone payments plus tiered royalties of 2.5%-10%.","Market opportunity ~$400M annually; affects ~2M cancer patients per year.","Aries to lead clinical development and commercialization; Enveric to focus on neuropsychiatric.","Aries nominates Hari Harikumar as chairman-elect of subsidiary formed for this product."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-027235","json":"https://secwatch.observer/filing/0001493152-24-027235.json","markdown":"https://secwatch.observer/filing/0001493152-24-027235.md","text":"https://secwatch.observer/filing/0001493152-24-027235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224027235/0001493152-24-027235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224027235/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:54:08.140735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}